Hormonal therapy and targeted therapy are available for estrogen receptor-positive and HER2-positive breast cancers; however, triple-negative breast cancers (15–20% of total breast cancers) are more difficult to manage and mainly rely on chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.